# Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

> **NCT01725113** · PHASE4 · TERMINATED · sponsor: **Winthrop University Hospital** · enrollment: 16 (actual)

## Conditions studied

- Kidney Failure
- Secondary Hyperparathyroidism
- Hyperphosphatemia
- Hypercalcemia

## Interventions

- **DRUG:** Calcitriol
- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT01725113
- **Lead sponsor:** Winthrop University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2013-12
- **Final completion:** 2015-10
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Nationwide shortage of study meds in 2013 loss of funding \& competing studies
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725113, "Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01725113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*